15/03/2019 19:00:00

(LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc.  ("Lexicon " or the "Company") (NASDAQ: LXRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Lexicon securities between March 11, 2016, and January 17, 2019, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/lxrx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (2) the health risks posed by Sotagliflozin were severe enough to threaten its FDA approval prospects; and (3) as a result, Lexicon’s public statements were materially false and misleading at all relevant times.

On January 17, 2019, Lexicon announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration had “voted eight to eight on the question of whether the overall benefits of [Lexicon’s product] Zynquista (sotagliflozin) outweighed the risks to support approval.”  On news of the advisory committee’s stalemate, Lexicon’s stock price fell $1.74 per share, or 22.6%, to close at $5.96 per share on January 18, 2019.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/lxrx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Lexicon you have until April 1, 2019 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

BGG Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
I:SP500
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
71
25 Mar
BAVA
En ting er, at du sylter os ind i dit misforståede bavl om BAVA. Det er, hvad det er.    Noget andet..
15
23 Mar
 
Hej Kanonkugle   Der er endnu ikke inversrentekurve i USA, det måles som forskellen mellem den 2 og ..
15
19 Mar
VELO
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
14
23 Mar
CHEMM
Chemometec er ikke i nedtrend som helhed. Aktien har haft en foreløbig top. Har fundet en bund som e..
12
21 Mar
BAVA
Jeg synes bestemt også der skal være plads til kritikere af Bavarian. Der skal være plads til alle i..
12
21 Mar
PNDORA
Du rammer jo netop ned i strategien "NOW", hvor der kigges ind i hvilke butikker der er lønsomme. Sa..
12
20 Mar
ZEAL
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
12
25 Mar
 
Jeg tror ikke Theresa May overlever dette inferno, hun selv har en stor del af ansvaret for. Det ene..
11
21 Mar
I:SP500
Der er en alt afgørende ting som Rangvid ikke tager højde for, og som Lars Christensen glemmer at kr..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UKTW I²P Celebrates First Successful Year of UK-TW Science Research Cooperation
2
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
3
Reminder - Product Tanker, Crude Oil Tanker, LNG, LPG and Chemical Tankers Sector Panel Discussions With Major Shipping Company Executives
4
Invitation by Aperam S.A. to holders of its outstanding U.S.$300,000,000 0.625 per cent. Net Share Settled Convertible and/or Exchangeable Bonds due 2021 (ISIN XS1084287322) (the “Bonds”) convertible into common shares of Aperam S.A. to off
5
Philips expands its radiology solutions offering with advanced teleradiology services

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 March 2019 03:02:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB4 - 2019-03-26 04:02:41 - 2019-03-26 03:02:41 - 1000 - Website: OKAY